Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $985.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price hoisted by BMO Capital Markets from $960.00 to $985.00 in a research report report published on Monday morning, Marketbeat.com reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other research analysts have also commented on REGN. StockNews.com initiated coverage […]